In the month of February, Bristol-Myers Squibb Co (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) reported that the firms have executed an international strategic commercialization and development collaboration for Nektar’s key immuno-oncology program named NKTR-214.
Under the collaboration, both firms will jointly commercialize and develop NKTR-214 in combination with Bristol-Myers’s Opdivo and Opdivo plus Yervoy in over 20 indications across nine tumor types, and prospective arrangements with other anti-cancer agents from third parties and/or either of the respective firms. Giovanni Caforio, M.D., the CEO and Chairman of Bristol-Myers, expressed that they are thrilled to bring their expertise and leading capabilities in advancing cancer treatments together with Nektar’s unique science to jointly commercialize and develop NKTR-214 in combination with Opdivo plus Yervoy and Opdivo.
Bristol-Myers Squibb has set Opdivo plus Yervoy as the single permitted immunotherapy combination for people with cancer and establish a strong oncology pipeline. With this dedication to the advancement of NKTR-214, they now have a third approved I-O mechanism that has shown clinical benefit in patients, and boasts considerable potential to expand the many benefits that these immuno-oncology agents stand to offer to people with cancer.
Nektar and Bristol-Myers Squibb have agreed to a joint clinical advancement plan to assess NKTR-214 with Opdivo plus Yervoy and Opdivo in registration-enabling clinical studies in over 20 indications in nine tumor types including non-small cell lung cancer, renal cell carcinoma, melanoma, triple negative breast and bladder cancer.
Howard Robin, the CEO and President of Nektar, expressed that Bristol-Myers, the international pioneer in immuno-oncology, is the model collaborator to allow them to establish NKTR-214 as a mainstay immunotherapy in the cancer treatment. NKTR-214’s ability to result in tumor infiltrating lymphocytes in vivo and refill the immune system is critically vital as many people fighting cancer lack sufficient tumor infiltrating lymphocytes populations to benefit from permitted checkpoint inhibitor therapies.